CN117624350A - Anti-human phosphorylated tau217 rabbit monoclonal antibody and application thereof - Google Patents
Anti-human phosphorylated tau217 rabbit monoclonal antibody and application thereof Download PDFInfo
- Publication number
- CN117624350A CN117624350A CN202311579238.XA CN202311579238A CN117624350A CN 117624350 A CN117624350 A CN 117624350A CN 202311579238 A CN202311579238 A CN 202311579238A CN 117624350 A CN117624350 A CN 117624350A
- Authority
- CN
- China
- Prior art keywords
- tau217
- monoclonal antibody
- rabbit monoclonal
- human phosphorylated
- phosphorylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000283973 Oryctolagus cuniculus Species 0.000 title claims abstract description 55
- 238000001514 detection method Methods 0.000 claims abstract description 46
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 17
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 17
- 238000003118 sandwich ELISA Methods 0.000 claims abstract description 13
- 238000003018 immunoassay Methods 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 238000003259 recombinant expression Methods 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 239000000427 antigen Substances 0.000 abstract description 15
- 102000036639 antigens Human genes 0.000 abstract description 15
- 108091007433 antigens Proteins 0.000 abstract description 15
- 238000000034 method Methods 0.000 abstract description 15
- 239000006249 magnetic particle Substances 0.000 abstract description 9
- 230000035945 sensitivity Effects 0.000 abstract description 8
- 102000013498 tau Proteins Human genes 0.000 description 15
- 108010026424 tau Proteins Proteins 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 14
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 102000029749 Microtubule Human genes 0.000 description 10
- 108091022875 Microtubule Proteins 0.000 description 10
- 210000004688 microtubule Anatomy 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 208000024827 Alzheimer disease Diseases 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000012089 stop solution Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000005002 finish coating Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Plasma & Fusion (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The application belongs to the technical field of immunodetection, and discloses an anti-human phosphorylated tau217 rabbit monoclonal antibody and application thereof. The anti-human phosphorylated tau217 rabbit monoclonal antibody provided by the application comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises LCDR1-3, the LCDR1-3 sequentially and respectively comprises an amino acid sequence shown as SEQ ID NO 3-5, the heavy chain variable region comprises HCDR1-3, and the HCDR1-3 sequentially and respectively comprises an amino acid sequence shown as SEQ ID NO 6-8. The rabbit monoclonal antibody can be combined with human phosphorylated tau217 protein in a high specificity way, the human phosphorylated tau217 standard antigen is detected by adopting the anti-human phosphorylated tau217 rabbit monoclonal antibody through double antibody sandwich ELISA, the detection sensitivity is less than 75pg/ml, and simultaneously, the human phosphorylated tau217 standard antigen is detected by adopting the anti-human phosphorylated tau217 rabbit monoclonal antibody through a magnetic particle chemiluminescence method, and the detection sensitivity can reach 50pg/ml.
Description
Technical Field
The application relates to the technical field of immunodetection, in particular to an anti-human phosphorylated tau217 rabbit monoclonal antibody and application thereof.
Background
Alzheimer's disease (Alzheimer disease, AD), commonly known as senile dementia, is a central neurodegenerative disease. Clinical manifestations are neuropsychiatric symptoms such as progressive memory impairment, cognitive dysfunction, personality changes and language impairment, and their typical histopathological changes are senile plaques caused by deposition of beta amyloid (Abeta), neurofibrillary tangles caused by abnormal phosphorylation of Tau protein, and loss of neurons and synapses. According to the international Alzheimer's disease society, more than 5000 tens of thousands of people worldwide are counted to have dementia, and by 2050, the number is increased to 1.52 hundred million, while about 1000 tens of thousands of people in China are the most abundant countries, and with the acceleration of population aging, 4000 tens of thousands of people are expected to be in China in 2050.
Tau protein is widely existing in living bodies, is a protein coded by chromosome 17 of a human body, particularly a nervous system, is a main component composing microtubules, and has functions of promoting microtubule assembly and maintaining microtubule stability. In the course of AD onset, microtubule structure changes, the integrity of microtubule structure is destroyed, dissociation of tubulin is promoted, and stability is destroyed. While tau protein bound to microtubules is also changed, hyperphosphorylated tau protein loses its biological activity in whole or in part, not only is binding force of the tau protein to the microtubules reduced, but also competes with normal microtubules to bind to the microtubules, thereby depolymerizing the microtubules, leading to degeneration of neurons starting from the protruding ends of the neurons, and finally leading to death of neurons and occurrence of AD.
According to the difference of phosphate sites, the P-Tau mainly comprises P-Tau181, P-Tau231, P-Tau217 and the like, and the diagnosis and treatment guide (2020 edition) of Alzheimer's disease dementia in China indicates that blood routine, biochemical and serological examination should be recommended in the routine examination flow of AD differential diagnosis, and the P-Tau217 concentration can be used as a biomarker for distinguishing AD from non-AD dementia in the blood examination.
At present, ELISA detection kit is mainly used for detecting Tau protein phosphorylation, namely, monoclonal antibodies which specifically recognize P-Tau217 are needed, but no report on rabbit monoclonal antibodies and detection methods exists, so that in order to better realize screening and diagnosis of Alzheimer's disease in the whole clinical process, anti-human phosphorylated Tau217 rabbit monoclonal antibodies and detection methods which have good specificity and high affinity for blood P-Tau217 are needed.
Disclosure of Invention
In order to overcome the technical problems, the application provides the anti-human phosphorylated tau217 rabbit monoclonal antibody with good specificity and high affinity, and the application of the anti-human phosphorylated tau217 rabbit monoclonal antibody in an immunodetection kit prepared by a double antibody sandwich ELISA or a chemiluminescence method, so as to provide auxiliary diagnosis for Alzheimer's disease and senile dementia related to human phosphorylated tau217, and strive for effective time for early diagnosis, timely intervention and treatment of diseases.
In a first aspect, the present application provides a rabbit monoclonal antibody against human phosphorylated tau217, the rabbit monoclonal antibody comprising a light chain variable region and a heavy chain variable region;
the rabbit monoclonal antibody comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises LCDR1-3, the LCDR1-3 sequentially comprises amino acid sequences shown as SEQ ID NO. 3-5 respectively, the heavy chain variable region comprises HCDR1-3, and the HCDR1-3 sequentially comprises amino acid sequences shown as SEQ ID NO. 6-8 respectively.
Alternatively, the light chain variable region comprises the amino acid sequence shown as SEQ ID NO.1, VL of 107 amino acids in full length, FR of 26, 17, 31 and 10 amino acids in 4 domains, LCDR of 7, 3 and 8 amino acids in3 domains, LCDR1, LCDR2 and LCDR3 of 27aa-33aa,51aa-53aa and 90aa-97aa, respectively, in amino acid sequence QSISTY (SEQ ID NO. 3), RAS (SEQ ID NO. 4) and LYGYRSTS (SEQ ID NO. 5), respectively.
The heavy chain variable region comprises an amino acid sequence shown as SEQ ID NO.2, the total length of VH is 117 amino acids, the amino acid numbers of 4 domains of FR are 25, 17, 38 and 11 respectively, the amino acid numbers of 3 domains of HCDR are 9, 7 and 10 respectively, HCDR1, HCDR2 and HCDR3 are 26aa-34aa,52aa-58aa and 97aa-106aa respectively, and the amino acid sequences are GFSFSNSYY (SEQ ID NO. 6), ISTVSNT (SEQ ID NO. 7) and ARGYVISSGY (SEQ ID NO. 8) respectively.
In a second aspect, the present application also provides an isolated polynucleotide encoding the rabbit monoclonal antibody of the first aspect against human phosphorylated tau 217.
In a third aspect, the present application also provides a recombinant expression vector comprising a polynucleotide according to the second aspect of the present application.
In a fourth aspect, the present application also provides a host cell comprising the recombinant expression vector of the third aspect, preferably the host cell is a prokaryotic cell or a eukaryotic cell.
In a fifth aspect, the application also provides the use of the rabbit monoclonal antibody of the first aspect in the preparation of an immunoassay product for detecting human phosphorylated tau217 protein.
Optionally, the immunodetection product is a detection kit, a chip or a detection test paper.
Optionally, the detection kit is a double-antibody sandwich ELISA detection kit or a chemiluminescent immunoassay kit.
In a sixth aspect, the present application also provides an immunoassay product for detecting human phosphorylated tau217, the immunoassay product comprising a rabbit monoclonal antibody as described in the first aspect of the present application.
Optionally, the immunodetection product is a detection kit, a chip or a detection test paper.
Compared with the prior art, the rabbit monoclonal antibody of the anti-human phosphorylated tau217 can be combined with the human phosphorylated tau217 protein in a high specificity, and the affinity constant Ka of the rabbit monoclonal antibody and the human phosphorylated tau217 protein can reach 7.6X10 8 L/mol, has high affinity. The rabbit monoclonal antibody of the anti-human phosphorylated tau217 can also be prepared into various immunodetection kits for detecting the phosphorylated tau217, and particularly can be applied to immunodetection kits prepared by a double antibody sandwich ELISA or a chemiluminescence method. The double-antibody sandwich ELISA detects the human phosphorylated tau217 standard antigen, and the detection sensitivity is less than 75pg/ml; the detection sensitivity of the magnetic particle chemiluminescence method for detecting the human phosphorylated tau217 standard antigen can reach 50pg/ml.
Drawings
FIG. 1 is an electrophoretogram of full-length amplification products of heavy and light chains of the rabbit monoclonal antibody OTIR3A11, M is a DNA molecular weight Marker.
FIG. 2 shows the detection of human phosphorylated tau217 polypeptides, non-phosphorylated tau217 polypeptides, human phosphorylated tau217 full-length proteins and non-phosphorylated full-length tau protein samples by indirect sandwich ELISA, with the ordinate indicating the OD values detected.
FIG. 3 shows the detection of human phosphorylated tau217 standard antigen by double antibody sandwich ELISA, the abscissa shows the concentration (ng/ml) of human phosphorylated tau217 standard antigen and the ordinate shows the OD value of the detection. R of standard curve 2 = 0.9983, linear detection range 0-10000pg/mL, and the sample concentration calculation formula is deduced: y=0.0002x+0.1083.
Detailed Description
The invention will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. The experimental procedures, which do not address the specific conditions in the examples below, are generally performed under conventional conditions, those described in the laboratory manual, or those suggested by the manufacturer.
Example 1 preparation of anti-human phosphorylated tau217 rabbit monoclonal antibodies
1) Preparation of human phosphorylated tau217 immunogen
The immunogenic polypeptide is designed according to tau protein (NP 005901.2) (2N 4R variant) 1-441aa sequence, the polypeptide sequence is 200-230aa, and the purity of the polypeptide is over 90%, so that the purity requirement for preparing monoclonal antibody is met. The polypeptides were synthesized by peptide biochemistry limited in a third party.
2) Immunization of animals
The synthesized human phosphorylated tau217 polypeptide is emulsified by complete Freund's adjuvant in a volume ratio of 1:1, about 2kg of New Zealand white rabbits are immunized by subcutaneous injection, the immunization dose is 800 mug/animal, the immunization is carried out for the second time after two weeks, the incomplete Freund's adjuvant is emulsified in a volume ratio of 1:1, and the immunization dose is 400 mug/animal. Tail blood is taken after two times of immunization, and serum titer is measured by ELISA method gradient dilution; and judging whether to collect PBMCs or continue immunization according to the result by taking OD450 at ELISA titer 128000 as a standard and selecting rabbits with highest antibody titers for collecting the PBMCs.
3) PBMCs separation, specific B cell separation, cloning recombination
Fixing rabbit on operation table, removing hair from heart, sterilizing skin with alcohol, selecting the most obvious heart beat, puncturing with 50ml syringe, injecting blood into syringe after needle, rapidly removing needle after obtaining required blood volume, transferring whole blood in syringe into sterile 50ml tube, mixing with equal amount of PBS, slowly adding dropwise above lymphocyte separating liquid, centrifuging at room temperature 400×g for 30min, and separating liquid level into four layers from top to bottom: the rabbit PBMCs are obtained by carefully sucking the mononuclear cell layer and washing and removing the platelet and lymphocyte separating liquid by PBS.
Antigen-specific B cells were further sorted from rabbit PBMCs for culture, and the supernatant of the cultured B cells was screened for positive clones using antigen-coated ELISA plates. The positive cloned cells are collected, lysed, RNA is extracted and reversely transcribed into cDNA, the natural paired rabbit monoclonal antibody light chain and heavy chain full-length sequences are amplified from the cDNA corresponding to the positive clone, a rabbit monoclonal antibody expression vector is constructed by a cloning recombination method, the sequences are determined by sequencing, and the amplified full-length PCR product results are shown in figure 1.
4) Preparation and purification of monoclonal antibodies
To obtain a plurality of rabbit monoclonal antibodies recognizing human phosphorylated tau217 protein, heavy chain and light chain genes of the rabbit monoclonal antibodies are loaded on an expression vector, KEK293 cells are transfected by plasmids, and the recombinant rabbit monoclonal antibodies recognizing human phosphorylated tau217 protein are obtained from culture supernatants after 120-144 hours of transfection. Collecting cell suspension, centrifuging to obtain supernatant, and performing antibody purification by affinity chromatography. The concentration of the purified monoclonal antibody was measured by BCA method, and then sub-packaged and lyophilized to give the purified antibody designated rabbit monoclonal antibody otor 3a11.
Example 2 identification of anti-human phosphorylated tau217 rabbit monoclonal antibody OTIR3A11
1) Specificity identification of Rabbit monoclonal antibodies
Indirect ELSA assay was used. Coating ELISA plate with human phosphorylated tau217 polypeptide, non-phosphorylated tau217 polypeptide, human phosphorylated tau217 full-length protein and non-phosphorylated full-length tau protein, sealing ELISA plate with PBST containing 1% BSA at 4deg.C overnight at 1 μg/ml, adding 10 4 The purified rabbit monoclonal antibody OTIR3A11 subjected to double dilution is reacted for 50min at 37 ℃, PBST is washed for 3 times, HRP-goat anti-rabbit Ig secondary antibody is added, the reaction is carried out for 50min at 37 ℃, PBST is washed for 5 times, TMB is added for color development for 10min, stop solution is added, and A450 is measured by an enzyme-labeled instrument.
FIG. 2 shows that both the non-phosphorylated tau217 polypeptide and the non-phosphorylated full-length tau protein react negatively with the rabbit monoclonal antibody OTIR3A11, with OD450 less than 0.1; the human phosphorylated tau217 polypeptide and the human phosphorylated tau217 full-length protein react positively with the OTIR3A11 antibody, and OD450 is larger than 1, which shows that the anti-human phosphorylated tau217 rabbit monoclonal antibody OTIR3A11 specifically recognizes a threonine (T) phosphorylation site epitope at position 217 in tau protein.
2) Affinity constant determination of rabbit monoclonal antibodies
Affinity constants (Ka) were determined by non-competitive ELISA.
Coating: diluting antigen with carbonate buffer solution to concentration of 1, 0.5, 0.1 and 0.05 mug/mL, respectively coating the antigen with 96-well ELISA plates according to 100 mug/well, and incubating for 24 hours at 4 ℃;
closing: the plates were washed 4 times with PBST, BSA solution was added at 200. Mu.L/well and incubated for 2h at 37 ℃;
adding monoclonal antibody: plates were washed 4 times with PBST, and mab OTIR3A11 was diluted with carbonate buffer starting at a doubling ratio of 100. Mu.g/mL, added 100. Mu.L per well and incubated for 2h at 37 ℃;
adding enzyme-labeled secondary antibodies: washing the plate with PBST for 4 times, adding 100 mu L of L10000 times diluted goat anti-rabbit Ig secondary antibody at 37 ℃ into each hole, and standing for 30min;
color development and termination: washing the plate with PBST for 4 times, adding 100 mu L of substrate color development liquid into each hole, and carrying out light-shielding reaction for 15min at 37 ℃; 50. Mu.L of 1.0mol/L H was added to each well 2 SO 4 A stop solution for stopping the reaction;
and (3) detection: the absorbance at a wavelength of 450nm (A450 nm) was measured.
Drawing an S-shaped curve by taking the logarithm of the concentration of the antibody as the abscissa and the OD value as the ordinate, and calculating the affinity constant Ka=7.6x10 of the anti-human phosphorylated tau217 rabbit monoclonal antibody OTIR3A11 8 L/mol。
3) Antibody pairing
To select the optimal combination of coated and detection antibodies, three purified rabbit monoclonal antibodies, OTIR1B11, OTIR1A10 and OTIR3A11, were coated on the ELISA plate, respectively, overnight at 4 ℃. The enzyme label plate is taken out the next day, PBST is washed once, 1% BSA solution is blocked for 2 hours at 37 ℃, and PBST is washed 3 times; 100 μl of human phosphorylated tau217 full-length protein was added to each well at a concentration of 20ng/ml and incubated for 1 hour at 37deg.C; after the incubation, the ELISA plate was removed, washed 3 times with PBST, and HRP-labeled murine monoclonal antibody OTI9A5 was added as a detection antibody, and incubated at 37℃for 1 hour. PBST was washed 5 times, TMB substrate was added, and color development was performed at 37℃for 10min. After removal, stop solution was added and OD450 readings were measured on an microplate reader. The optimal rabbit monoclonal antibody pair is selected according to the OD value of the sample and the background value of the negative control, and the pairing screening result is shown in Table 1.
Table 1 results of screening of antibody pairing experiments
It can be seen that the antibody OTIR3A11 referred to in this application was the best coated antibody, and murine monoclonal antibody OTI9A5 was the best detection antibody.
Example 3 analysis of variable region Gene and amino acid sequence of rabbit monoclonal antibody OTIR3A11 recombinant plasmid of OTIR3A11 antibody was used as DNA template, light chain variable region and heavy chain variable region sequencing primers were designed based on the 5' -end vector sequences of the light chain and heavy chain on the template, and sequencing was performed using sequencer ABI 3730. The nucleotide sequence of the variable region of the light chain and the heavy chain of the rabbit monoclonal antibody OTIR3A11 is obtained through sequencing.
The nucleotide sequences of the light chain variable region and the heavy chain variable region are respectively subjected to sequencing result data analysis by using IMGT/V-QUEST analysis software on http:// www.imgt.org through the Internet, the amino acid sequence of the light chain variable region of the rabbit monoclonal antibody OTIR3A11 is shown as SEQ ID NO.1, and the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO. 2. VL is 107 amino acids in full length, the number of 4 domain amino acids of FR is 26, 17, 31 and 10 respectively, the number of 3 domain amino acids of LCDR is 7, 3 and 8 respectively, and the regions of LCDR1, LCDR2 and LCDR3 are 27aa-33aa,51aa-53aa and 90aa-97aa respectively, the amino acid sequences of which are QSISTY (SEQ ID NO. 3), RAS (SEQ ID NO. 4) and LYGYRSTS (SEQ ID NO. 5) respectively; the total length of VH is 117 amino acids, the number of 4 domain amino acids of FR is 25, 17, 38 and 11 respectively, the number of 3 domain amino acids of HCDR is 9, 7 and 10 respectively, HCDR1, HCDR2 and HCDR3 are 26aa-34aa,52aa-58aa and 97aa-106aa respectively, and the amino acid sequences thereof are GFSFSNSYY (SEQ ID NO. 6), ISTVSNT (SEQ ID NO. 7) and ARGYVISSGY (SEQ ID NO. 8) respectively.
Example 4 anti-human phosphorylated tau217 rabbit monoclonal antibody OTIR3A11 is used for preparing double antibody sandwich ELISA detection kit based on ELISA double antibody sandwich principle detection technique, human phosphorylated tau217 detection kit is prepared for clinical auxiliary diagnosis of diseases related to human phosphorylated tau 217.
1. Kit composition
1. Laths coated with OTIR3A11 antibodies: diluting the antibody to 1 mug/ml with PBS buffer, coating onto a microplate, incubating overnight at 4 ℃ with 100 mug/well, washing 3 times with PBST, and spin-drying; blocking with PBS containing 1% BSA, 5% sucrose and 0.05% proclin300, reacting at 37deg.C for 2 hr, discarding the blocking solution in the hole, and drying; and (3) placing the coating plate in a baking oven at 37 ℃ for 2 hours to finish coating, sealing by an aluminum foil bag, and storing at 4 ℃ for standby.
2. Reagent preparation
2.1 preparation of enzyme conjugate the simple sodium periodate method is adopted to label anti-human non-phosphorylated tau protein mouse monoclonal antibody OTI9A5, the working concentration is titrated, 1:20 concentration solution is prepared, the dilution solution is PBS containing 1% BSA, 5% glycerol and 0.05% Proclin300, and filtering and sterilizing are carried out.
2.2 washing buffer was conventional PBST at pH7.4 containing 0.05% Proclin300 and was formulated as a 20-fold concentrate.
2.3 substrate solution (color developing solution) of enzyme one-component TMB (purchased from market).
2.4 sample dilutions contained 1% BSA, 0.05% Proclin300 in PBS, and were sterilized by filtration.
2.5 stop solution 10ml HCl (36-38%) was added to 110ml distilled water and the mixing was slowly performed to prepare 1N HCl.
2.6 Standard full Length human phosphorylated tau217 protein, samples were diluted to 20 μg/ml with PBS containing 1% BSA, 5% sucrose, 10% glycerol, 0.05% Proclin300 as dilution, filtered, sterilized and aseptically sub-packaged.
2. Detecting the operation key points
1. In order to ensure the accuracy of the detection result, it is suggested that both the standard and the sample are provided with double-hole measurement. Standard curves are needed for each detection.
2. If the content of the substance to be detected in the sample is too high, the sample is diluted by the sample diluent to ensure that the sample accords with the detection range of the kit, and finally, the sample is multiplied by the corresponding dilution multiple during calculation.
3. Sample adding: during sample addition, a disposable clean suction head is required to be used, so that cross contamination is avoided. The sample should be added as slowly as possible to avoid foaming, and the sample is added at the bottom of the ELISA plate hole without adding the sample along the hole wall.
4. Incubation: in order to prevent sample evaporation or contamination, the ELISA plate must be covered and attached during incubation, and the ELISA plate should be prevented from being in a dry state during the experiment. During the incubation process, whether the temperature of the incubator is constant at 37 ℃ or not should be observed at any time, and the temperature should be adjusted in time. During the incubation, the incubator is not easily opened too many times to avoid affecting the temperature balance.
5. Washing: the washing process is very important, and insufficient washing is prone to false positives.
6. Color development: in order to ensure the accuracy of the experimental result, the stop solution should be added as soon as possible after the substrate reaction time. The color development can be observed at intervals after the substrate solution is added to control the reaction time (e.g., at intervals of 10 minutes). When the front 3-4 holes of the standard product are visible to naked eyes and have obvious gradient blue, and the color development of the rear 3-4 holes is not obvious, stopping solution can be added to stop the reaction, and the blue color immediately turns yellow. The order of addition of the stop solution should be as similar as possible to the order of addition of the substrate solution.
7. The substrate solution should be bluish or colorless and must be discarded if the color becomes severely darkened. The substrate solution is easy to be polluted and is required to be preserved properly in dark place.
3. Determination of standard human phosphorylated tau217 protein different dilutions standard curve
The prepared double-antibody sandwich ELISA detection kit for detecting the human phosphorylated tau217 protein is taken out from a refrigerator at 4 ℃ and balanced to the room temperature. The standard was diluted from 20. Mu.g/ml to 10000pg/ml with PBS to prepare 8 series concentration standard substances of 0, 150, 300, 600, 1200, 2500, 5000, 10000pg/ml, 100. Mu.l of the standard substance was added to each well for incubation according to the above detection method, then the liquid was discarded, an HRP-labeled detection antibody working solution was added for incubation, the liquid in the well was discarded, a substrate solution was added to each well after spin-drying, a stop solution was added to each well after development in the absence of light, and the optical density OD value of each well was measured sequentially at a wavelength of 450nm with an enzyme-labeled instrument within 5 minutes after termination of the reaction to make a standard curve, and the results are shown in Table 2.
Table 2 double antibody sandwich ELISA method for detecting human phosphorylated tau217 standard substance
A standard curve for human phosphorylated tau217 was generated according to Table 2, see FIG. 3. R of standard curve 2 = 0.9983, linear detection range 0-10000pg/mL, and the sample concentration calculation formula is deduced: y=0.0002x+0.1083, and the detection sensitivity is less than 75pg/ml.
EXAMPLE 5 anti-human phosphorylated tau217 rabbit monoclonal antibody OTIR3A11 for magnetic particle chemiluminescent immunoassay
1. Detection principle and method
Adopts a magnetic particle chemiluminescence immunoassay technology based on the principle of a double-antibody sandwich method. Biotin marks a rabbit monoclonal antibody OTIR3A11 of anti-human phosphorylated tau217, the biotinylated OTIR3A11 is fixed with SA magnetic beads, ALP is coupled with a non-phosphorylated tau protein mouse monoclonal antibody OTI9A5, and meanwhile, the full-length protein of the human phosphorylated tau217, an ALP substrate and corresponding buffer components are placed on a Kestelmi full-automatic magnetic particle chemiluminescence instrument, and an instrument program is set for detection. And judging that the result is positive according to the fact that the signal to noise ratio of the luminescence value is larger than 2.0. The magnitude of the luminescence value reflects the amount of bound enzyme-labeled antibody, which is proportional to the concentration of human phosphorylated tau217 in the sample. And drawing a standard curve according to the measured luminous value of the standard substance, wherein the concentration value of the human phosphorylated tau217 in the sample to be measured can be obtained from the standard curve.
2. Magnetic particle chemiluminescence detection kit for detecting human phosphorylated tau217
SA magnetic bead binding biotin-OTIR 3A11: taking 50 μl of magnetic beads into a 0.5ml centrifuge tube, placing on a magnetic rack, and removing supernatant after 1 min; washing the beads 3 times with 0.5ml of antibody dilution; adding a certain amount of biotin-labeled OTIR3A11, and mixing at room temperature for 60min; after magnetic separation, the suspension was resuspended in magnetic preservation buffer at a working concentration of 0.5mg/ml.
OTI9A5 coupled ALP: the antibody OTI9A5 was first reduced using 2-IT; and secondly, ALP-SMCC intermediate formation is carried out, and finally, ALP-SMCC is coupled with a reducing antibody. After the coupling, the mixture was diluted to the working concentration using ALP preservation buffer.
3. The wash buffer was the same as in example 4.
4. Chemiluminescent developer is purchased from lovir organisms.
5. The sample dilutions contained 1% BSA, 0.05% Proclin300 in PBST, and were sterilized by filtration.
6. Standard full-length human phosphorylated tau217 full-length protein, a sample is diluted to 5 mug/ml by using PBS containing 1% BSA, 5% sucrose, 10% glycerol and 0.05% procrin300 as a diluent, filtered, sterilized and aseptically packaged.
3. Detection of human phosphorylated tau217 standard antigen
The human phosphorylated tau217 standard antigen was subjected to gradient dilution of 0pg/ml, 50pg/ml, 100pg/ml, 200pg/ml, 500pg/ml, respectively, with OTIR3A11 antibody as the coating antibody and OTI9A5 antibody as the detection antibody, and 5 gradient diluted antigens were detected by the above detection method, and the detection results are shown in Table 3.
TABLE 3 detection of human phosphorylated tau217 Standard antigen by magnetic particle chemiluminescence
The rabbit monoclonal antibody OTIR3A11 is used for a magnetic particle chemiluminescence immunoassay reagent according to the judgment that the signal-to-noise ratio is greater than 2.0, wherein the lowest sensitivity is 50pg/ml, and the linear range is 0-500pg/ml.
In conclusion, the anti-human phosphorylated tau217 rabbit monoclonal antibody is applied to an immune detection kit prepared by a double-antibody sandwich ELISA or a chemiluminescence method, the double-antibody sandwich ELISA detects phosphorylated tau217 standard antigens, the detection sensitivity is less than 75pg/ml, and the detection sensitivity can reach 50pg/ml by a magnetic particle chemiluminescence method.
The present embodiment is merely illustrative of the present application and is not intended to be limiting, and those skilled in the art, after having read the present specification, may make modifications to the present embodiment without creative contribution as required, but is protected by patent laws within the scope of the claims of the present application.
Claims (10)
1. A rabbit monoclonal antibody against human phosphorylated tau217, comprising a light chain variable region comprising LCDR1-3, wherein LCDR1-3 comprises in sequence the amino acid sequences shown in SEQ ID NOs 3-5, respectively, and a heavy chain variable region comprising HCDR1-3, wherein HCDR1-3 comprises in sequence the amino acid sequences shown in SEQ ID NOs 6-8, respectively.
2. The rabbit monoclonal antibody of claim 1, wherein the light chain variable region comprises an amino acid sequence set forth in SEQ ID No.1 and the heavy chain variable region comprises an amino acid sequence set forth in SEQ ID No. 2.
3. An isolated polynucleotide encoding the rabbit monoclonal antibody of any one of claims 1-2.
4. A recombinant expression vector comprising the polynucleotide of claim 3.
5. A host cell comprising the recombinant expression vector of claim 4, wherein the host cell is a prokaryotic cell or a eukaryotic cell.
6. Use of a rabbit monoclonal antibody according to claim 1 or 2 for the preparation of an immunoassay product for detecting human phosphorylated tau217 protein.
7. The use according to claim 6, wherein the immunodetection product is a detection kit, a chip or a detection strip.
8. The use according to claim 7, wherein the detection kit is a double antibody sandwich ELISA detection kit or a chemiluminescent immunoassay kit.
9. An immunoassay product of human phosphorylated tau217, comprising the rabbit monoclonal antibody of claim 1 or 2.
10. The immunoassay product of claim 9, wherein the immunoassay product is a test kit, chip or test strip.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311579238.XA CN117624350B (en) | 2023-11-24 | 2023-11-24 | Anti-human phosphorylated tau217 rabbit monoclonal antibody and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311579238.XA CN117624350B (en) | 2023-11-24 | 2023-11-24 | Anti-human phosphorylated tau217 rabbit monoclonal antibody and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117624350A true CN117624350A (en) | 2024-03-01 |
| CN117624350B CN117624350B (en) | 2024-07-19 |
Family
ID=90022712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311579238.XA Active CN117624350B (en) | 2023-11-24 | 2023-11-24 | Anti-human phosphorylated tau217 rabbit monoclonal antibody and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117624350B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021128946A1 (en) * | 2019-12-26 | 2021-07-01 | 成都欧林生物科技股份有限公司 | Anti-spa5 protein monoclonal antibody, use thereof and kit containing same |
| CN113683688A (en) * | 2021-07-23 | 2021-11-23 | 无锡傲锐东源生物科技有限公司 | Rabbit monoclonal antibody against human immunodeficiency virus type I P24 antigen (HIV-1P24) and application thereof |
| CN113817062A (en) * | 2021-07-26 | 2021-12-21 | 无锡傲锐东源生物科技有限公司 | Rabbit monoclonal antibody against human hydroxysteroid 17-beta dehydrogenase 13(HSD17B13) and application thereof |
-
2023
- 2023-11-24 CN CN202311579238.XA patent/CN117624350B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021128946A1 (en) * | 2019-12-26 | 2021-07-01 | 成都欧林生物科技股份有限公司 | Anti-spa5 protein monoclonal antibody, use thereof and kit containing same |
| CN113683688A (en) * | 2021-07-23 | 2021-11-23 | 无锡傲锐东源生物科技有限公司 | Rabbit monoclonal antibody against human immunodeficiency virus type I P24 antigen (HIV-1P24) and application thereof |
| CN113817062A (en) * | 2021-07-26 | 2021-12-21 | 无锡傲锐东源生物科技有限公司 | Rabbit monoclonal antibody against human hydroxysteroid 17-beta dehydrogenase 13(HSD17B13) and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117624350B (en) | 2024-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI283749B (en) | Antibody pair screening methods | |
| WO2005047860A2 (en) | Antibodies to alpha-synuclein | |
| CN117624351B (en) | Anti-human phosphorylated tau181 rabbit monoclonal antibody and application thereof | |
| WO2007021255A1 (en) | Antibodies to alpha-synuclein | |
| CN114181908B (en) | Anti-human S100B protein mouse monoclonal antibody and application thereof | |
| CN117624354B (en) | Anti-human acetylated tau281 rabbit monoclonal antibody and application thereof | |
| WO2013035799A1 (en) | Antibody capable of binding to specific region of periostin, and method for measuring periostin using same | |
| CN113683688B (en) | anti-HIV type I P24 antigen (HIV-1P 24) rabbit monoclonal antibody and application thereof | |
| US7682795B2 (en) | Method of diagnosing Alzheimer's Disease | |
| CN113817062B (en) | Anti-human hydroxysteroid 17-beta dehydrogenase 13 (HSD 17B 13) rabbit monoclonal antibody and application thereof | |
| CN117624358B (en) | Abeta 1-40 specific antibody and application thereof in Alzheimer disease auxiliary diagnosis kit | |
| JP6048923B2 (en) | Detection method and detection kit for chronic hepatitis B | |
| JP4310389B2 (en) | Novel foam proteins and their use | |
| CN106939034B (en) | Methods and kits for identifying HEV genotypes infected by a subject | |
| CN117624350B (en) | Anti-human phosphorylated tau217 rabbit monoclonal antibody and application thereof | |
| CN113956355B (en) | Anti-human Brain Natriuretic Peptide (BNP) rabbit monoclonal antibody and application thereof | |
| US11307202B1 (en) | Antibody binding detection method for detecting MERS-CoV | |
| CN117624355B (en) | Anti-human acetylated tau274 rabbit monoclonal antibody and application thereof | |
| CN113912719A (en) | Monoclonal antibody for detecting mouse interleukin 6 and preparation method and application thereof | |
| EP3760641A1 (en) | Monoclonal antibody against apoa4, immunoassay method, and kit for measurement | |
| RU2297634C2 (en) | Drug addiction-revealing diagnostic reagent kit "narco-ifa-peptide test" | |
| CN117624357B (en) | P-Tau 217 specific antibody and application thereof in Alzheimer disease auxiliary diagnosis kit | |
| CN117820472B (en) | P-Tau 181 specific antibody and application thereof in Alzheimer disease auxiliary diagnosis kit | |
| RU2754791C1 (en) | Mosaic recombinant polypeptide containing fragments of hepatitis e virus proteins of genotypes 1 and 3 in one polypeptide chain, intended for use in test systems used in the serodiagnosis of hepatitis e | |
| WO2022265066A1 (en) | Sars-cov-2 immunoassay method and immunoassay kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |